25 XP   0   0   10

Shenzhen Salubris Pharmaceuticals Co Ltd
Buy, Hold or Sell?

Let's analyse Salubris together

PenkeI guess you are interested in Shenzhen Salubris Pharmaceuticals Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Shenzhen Salubris Pharmaceuticals Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Shenzhen Salubris Pharmaceuticals Co Ltd

I send you an email if I find something interesting about Shenzhen Salubris Pharmaceuticals Co Ltd.

Quick analysis of Salubris (30 sec.)










What can you expect buying and holding a share of Salubris? (30 sec.)

How much money do you get?

How much money do you get?
¥0.07
When do you have the money?
1 year
How often do you get paid?
92.5%

What is your share worth?

Current worth
¥7.23
Expected worth in 1 year
¥7.30
How sure are you?
82.5%

+ What do you gain per year?

Total Gains per Share
¥0.56
Return On Investment
1.9%

For what price can you sell your share?

Current Price per Share
¥29.97
Expected price per share
¥29.85 - ¥33.82
How sure are you?
50%

1. Valuation of Salubris (5 min.)




Live pricePrice per Share (EOD)

¥29.97

Intrinsic Value Per Share

¥1.67 - ¥16.94

Total Value Per Share

¥8.90 - ¥24.17

2. Growth of Salubris (5 min.)




Is Salubris growing?

Current yearPrevious yearGrowGrow %
How rich?$1.1b$1b$15.2m1.4%

How much money is Salubris making?

Current yearPrevious yearGrowGrow %
Making money$20m$21.9m-$1.9m-9.8%
Net Profit Margin17.3%18.2%--

How much money comes from the company's main activities?

3. Financial Health of Salubris (5 min.)




4. Comparing to competitors in the Medical Instruments & Supplies industry (5 min.)




  Industry Rankings (Medical Instruments & Supplies)  


Richest
#44 / 169

Most Revenue
#72 / 169

Most Profit
#56 / 169

What can you expect buying and holding a share of Salubris? (5 min.)

Welcome investor! Salubris's management wants to use your money to grow the business. In return you get a share of Salubris.

What can you expect buying and holding a share of Salubris?

First you should know what it really means to hold a share of Salubris. And how you can make/lose money.

Speculation

The Price per Share of Salubris is ¥29.97. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Salubris.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Salubris, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥7.23. Based on the TTM, the Book Value Change Per Share is ¥0.02 per quarter. Based on the YOY, the Book Value Change Per Share is ¥-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.12 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Salubris.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.010.0%0.020.1%0.020.1%0.020.1%0.030.1%
Usd Book Value Change Per Share0.010.0%0.000.0%0.000.0%0.010.0%0.020.1%
Usd Dividend Per Share0.000.0%0.020.1%0.010.0%0.010.0%0.030.1%
Usd Total Gains Per Share0.010.0%0.020.1%0.010.0%0.020.1%0.050.2%
Usd Price Per Share4.51-4.45-3.71-3.88-4.14-
Price to Earnings Ratio90.22-65.98-56.50--100.05--36.44-
Price-to-Total Gains Ratio330.26-240.14-638.47-274.26-126.89-
Price to Book Ratio4.52-4.49-3.80-4.40-5.90-
Price-to-Total Gains Ratio330.26-240.14-638.47-274.26-126.89-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.138857
Number of shares241
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.020.01
Usd Book Value Change Per Share0.000.01
Usd Total Gains Per Share0.020.02
Gains per Quarter (241 shares)4.695.34
Gains per Year (241 shares)18.7621.37
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1162914711
233528291432
349747432153
466966572874
5821285713595
698141048642116
71151612310049137
81311914211457158
91482116112964179
101642418014371200

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%18.02.00.090.0%38.02.00.095.0%56.02.00.096.6%
Book Value Change Per Share3.01.00.075.0%9.03.00.075.0%13.07.00.065.0%28.012.00.070.0%42.016.00.072.4%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%37.00.03.092.5%50.00.08.086.2%
Total Gains per Share4.00.00.0100.0%10.02.00.083.3%15.05.00.075.0%33.07.00.082.5%51.07.00.087.9%

Fundamentals of Salubris

About Shenzhen Salubris Pharmaceuticals Co Ltd

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also provides interventional medical devices for therapy of cardiovascular and cerebrovascular diseases, peripheral blood vessels, structural heart diseases, electrophysiology, and cardiac rhythm management. In addition, the company develops Sacubitril Allisartan Calcium, Allisartan Isoproxil Amlodipine Besylate Tablets, and Allisartan IsoproxilIndapamide Sustained-release Tablets, which are in phase III clinical trial for treatment of hypertension; Enarodustat, a drug for renal anemia; SAL056 medicine used for treating osteoporosis; and Fotagliptin and SAL015 for diabetes which are under phase III clinical trial. Further, it develops Sacubitril Allisartan Calcium and SAL007 medicine for chronic heart failure; SAL003 medicine that is in phase I clinical trial to treat hypercholesterolemia; and SAL0114 for depressant indications. Additionally, the company's preclinical products are SAL023 for osteoporosis; SAL0112 to treat diabetes; and SAL008 for the treatment of tumors. Furthermore, it develops medical devices, such as intracranial segment of vertebral artery stent, which is under clinical trials for Neurology intervention; SaExtenVena cava filter and Microneedle perfusion absolute ethanol delivery system used for Peripheral vascular intervention; and LAMax LAAC Left Atrial Appendage Occluder that is in clinical trials used for Structural heart disease. The company was founded in 1998 and is headquartered in Shenzhen, China. Shenzhen Salubris Pharmaceuticals Co., Ltd. is an operating subsidiary of Salubris Pharmaceuticals Co., Ltd.

Fundamental data was last updated by Penke on 2024-04-14 14:56:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Shenzhen Salubris Pharmaceuticals Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Salubris earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Salubris to the Medical Instruments & Supplies industry mean.
  • A Net Profit Margin of 11.1% means that ¥0.11 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Shenzhen Salubris Pharmaceuticals Co Ltd:

  • The MRQ is 11.1%. The company is making a huge profit. +2
  • The TTM is 17.3%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ11.1%TTM17.3%-6.2%
TTM17.3%YOY18.2%-0.9%
TTM17.3%5Y13.7%+3.6%
5Y13.7%10Y24.4%-10.8%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ11.1%6.2%+4.9%
TTM17.3%6.4%+10.9%
YOY18.2%8.0%+10.2%
5Y13.7%7.3%+6.4%
10Y24.4%6.8%+17.6%
1.1.2. Return on Assets

Shows how efficient Salubris is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Salubris to the Medical Instruments & Supplies industry mean.
  • 1.1% Return on Assets means that Salubris generated ¥0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Shenzhen Salubris Pharmaceuticals Co Ltd:

  • The MRQ is 1.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.1%TTM1.5%-0.4%
TTM1.5%YOY1.7%-0.1%
TTM1.5%5Y1.4%+0.1%
5Y1.4%10Y3.6%-2.2%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1%1.3%-0.2%
TTM1.5%1.4%+0.1%
YOY1.7%1.9%-0.2%
5Y1.4%2.1%-0.7%
10Y3.6%2.0%+1.6%
1.1.3. Return on Equity

Shows how efficient Salubris is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Salubris to the Medical Instruments & Supplies industry mean.
  • 1.3% Return on Equity means Salubris generated ¥0.01 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Shenzhen Salubris Pharmaceuticals Co Ltd:

  • The MRQ is 1.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.8%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.3%TTM1.8%-0.6%
TTM1.8%YOY2.0%-0.2%
TTM1.8%5Y1.7%+0.1%
5Y1.7%10Y4.3%-2.6%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3%2.6%-1.3%
TTM1.8%2.8%-1.0%
YOY2.0%3.7%-1.7%
5Y1.7%3.9%-2.2%
10Y4.3%3.9%+0.4%

1.2. Operating Efficiency of Shenzhen Salubris Pharmaceuticals Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Salubris is operating .

  • Measures how much profit Salubris makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Salubris to the Medical Instruments & Supplies industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Shenzhen Salubris Pharmaceuticals Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM15.8%-15.8%
TTM15.8%YOY17.9%-2.1%
TTM15.8%5Y16.1%-0.3%
5Y16.1%10Y10.5%+5.6%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.9%-7.9%
TTM15.8%7.6%+8.2%
YOY17.9%10.9%+7.0%
5Y16.1%10.1%+6.0%
10Y10.5%10.5%0.0%
1.2.2. Operating Ratio

Measures how efficient Salubris is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • An Operation Ratio of 1.16 means that the operating costs are ¥1.16 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Shenzhen Salubris Pharmaceuticals Co Ltd:

  • The MRQ is 1.162. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.124. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.162TTM1.124+0.038
TTM1.124YOY1.105+0.019
TTM1.1245Y1.102+0.022
5Y1.10210Y0.708+0.394
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1621.152+0.010
TTM1.1241.146-0.022
YOY1.1051.082+0.023
5Y1.1021.097+0.005
10Y0.7081.056-0.348

1.3. Liquidity of Shenzhen Salubris Pharmaceuticals Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Salubris is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A Current Ratio of 4.06 means the company has ¥4.06 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Shenzhen Salubris Pharmaceuticals Co Ltd:

  • The MRQ is 4.065. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.727. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.065TTM3.727+0.338
TTM3.727YOY3.036+0.691
TTM3.7275Y3.566+0.161
5Y3.56610Y2.187+1.380
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0652.310+1.755
TTM3.7272.339+1.388
YOY3.0362.575+0.461
5Y3.5662.627+0.939
10Y2.1872.623-0.436
1.3.2. Quick Ratio

Measures if Salubris is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Salubris to the Medical Instruments & Supplies industry mean.
  • A Quick Ratio of 0.80 means the company can pay off ¥0.80 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Shenzhen Salubris Pharmaceuticals Co Ltd:

  • The MRQ is 0.802. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.835. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.802TTM0.835-0.033
TTM0.835YOY0.495+0.339
TTM0.8355Y0.886-0.051
5Y0.88610Y1.618-0.732
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8021.105-0.303
TTM0.8351.137-0.302
YOY0.4951.306-0.811
5Y0.8861.430-0.544
10Y1.6181.533+0.085

1.4. Solvency of Shenzhen Salubris Pharmaceuticals Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Salubris assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Salubris to Medical Instruments & Supplies industry mean.
  • A Debt to Asset Ratio of 0.14 means that Salubris assets are financed with 14.3% credit (debt) and the remaining percentage (100% - 14.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Shenzhen Salubris Pharmaceuticals Co Ltd:

  • The MRQ is 0.143. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.158. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.143TTM0.158-0.015
TTM0.158YOY0.181-0.022
TTM0.1585Y0.159-0.001
5Y0.15910Y0.147+0.013
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1430.357-0.214
TTM0.1580.360-0.202
YOY0.1810.358-0.177
5Y0.1590.365-0.206
10Y0.1470.375-0.228
1.4.2. Debt to Equity Ratio

Measures if Salubris is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Salubris to the Medical Instruments & Supplies industry mean.
  • A Debt to Equity ratio of 16.7% means that company has ¥0.17 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Shenzhen Salubris Pharmaceuticals Co Ltd:

  • The MRQ is 0.167. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.189. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.167TTM0.189-0.022
TTM0.189YOY0.221-0.032
TTM0.1895Y0.193-0.004
5Y0.19310Y0.176+0.017
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1670.541-0.374
TTM0.1890.561-0.372
YOY0.2210.561-0.340
5Y0.1930.648-0.455
10Y0.1760.669-0.493

2. Market Valuation of Shenzhen Salubris Pharmaceuticals Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Salubris generates.

  • Above 15 is considered overpriced but always compare Salubris to the Medical Instruments & Supplies industry mean.
  • A PE ratio of 90.22 means the investor is paying ¥90.22 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Shenzhen Salubris Pharmaceuticals Co Ltd:

  • The EOD is 82.790. Based on the earnings, the company is expensive. -2
  • The MRQ is 90.221. Based on the earnings, the company is expensive. -2
  • The TTM is 65.985. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD82.790MRQ90.221-7.431
MRQ90.221TTM65.985+24.236
TTM65.985YOY56.504+9.481
TTM65.9855Y-100.052+166.037
5Y-100.05210Y-36.442-63.610
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD82.79014.579+68.211
MRQ90.22116.584+73.637
TTM65.98517.443+48.542
YOY56.50422.147+34.357
5Y-100.05220.830-120.882
10Y-36.44225.069-61.511
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Shenzhen Salubris Pharmaceuticals Co Ltd:

  • The EOD is 55.054. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 59.995. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 126.173. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD55.054MRQ59.995-4.941
MRQ59.995TTM126.173-66.178
TTM126.173YOY-155.306+281.479
TTM126.1735Y-1.022+127.195
5Y-1.02210Y13.605-14.627
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD55.0549.822+45.232
MRQ59.99510.068+49.927
TTM126.1731.387+124.786
YOY-155.3063.453-158.759
5Y-1.0225.897-6.919
10Y13.605-0.177+13.782
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Salubris is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A PB ratio of 4.52 means the investor is paying ¥4.52 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Shenzhen Salubris Pharmaceuticals Co Ltd:

  • The EOD is 4.148. Based on the equity, the company is fair priced.
  • The MRQ is 4.520. Based on the equity, the company is fair priced.
  • The TTM is 4.488. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.148MRQ4.520-0.372
MRQ4.520TTM4.488+0.032
TTM4.488YOY3.797+0.692
TTM4.4885Y4.402+0.086
5Y4.40210Y5.901-1.499
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD4.1482.398+1.750
MRQ4.5202.753+1.767
TTM4.4882.690+1.798
YOY3.7973.294+0.503
5Y4.4023.563+0.839
10Y5.9014.227+1.674
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Shenzhen Salubris Pharmaceuticals Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0990.018+459%-0.015+116%0.053+86%0.110-10%
Book Value Per Share--7.2267.173+1%7.074+2%6.487+11%5.502+31%
Current Ratio--4.0653.727+9%3.036+34%3.566+14%2.187+86%
Debt To Asset Ratio--0.1430.158-10%0.181-21%0.159-10%0.147-3%
Debt To Equity Ratio--0.1670.189-12%0.221-24%0.193-13%0.176-5%
Dividend Per Share--0.0000.123-100%0.099-100%0.107-100%0.216-100%
Eps--0.0910.130-30%0.143-37%0.113-20%0.205-56%
Free Cash Flow Per Share--0.1360.038+260%0.083+63%0.136+0%0.301-55%
Free Cash Flow To Equity Per Share--0.136-0.085+162%-0.043+132%0.088+55%0.264-48%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--16.945--------
Intrinsic Value_10Y_min--1.673--------
Intrinsic Value_1Y_max--1.279--------
Intrinsic Value_1Y_min--0.339--------
Intrinsic Value_3Y_max--4.161--------
Intrinsic Value_3Y_min--0.876--------
Intrinsic Value_5Y_max--7.429--------
Intrinsic Value_5Y_min--1.253--------
Market Cap33411154440.960-9%36410020154.88035913925269.120+1%29918980891.200+22%31302472471.488+16%33399727536.288+9%
Net Profit Margin--0.1110.173-36%0.182-39%0.137-19%0.244-55%
Operating Margin---0.158-100%0.179-100%0.161-100%0.105-100%
Operating Ratio--1.1621.124+3%1.105+5%1.102+5%0.708+64%
Pb Ratio4.148-9%4.5204.488+1%3.797+19%4.402+3%5.901-23%
Pe Ratio82.790-9%90.22165.985+37%56.504+60%-100.052+211%-36.442+140%
Price Per Share29.970-9%32.66032.215+1%26.838+22%28.079+16%29.960+9%
Price To Free Cash Flow Ratio55.054-9%59.995126.173-52%-155.306+359%-1.022+102%13.605+341%
Price To Total Gains Ratio303.059-9%330.260240.141+38%638.471-48%274.262+20%126.894+160%
Quick Ratio--0.8020.835-4%0.495+62%0.886-9%1.618-50%
Return On Assets--0.0110.015-29%0.017-35%0.014-25%0.036-70%
Return On Equity--0.0130.018-31%0.020-38%0.017-26%0.043-70%
Total Gains Per Share--0.0990.141-30%0.083+19%0.161-38%0.326-70%
Usd Book Value--1112454380.2811104363548.014+1%1089140242.659+2%998784882.877+11%847025533.092+31%
Usd Book Value Change Per Share--0.0140.002+459%-0.002+116%0.007+86%0.015-10%
Usd Book Value Per Share--0.9980.991+1%0.977+2%0.896+11%0.760+31%
Usd Dividend Per Share--0.0000.017-100%0.014-100%0.015-100%0.030-100%
Usd Eps--0.0120.018-30%0.020-37%0.016-20%0.028-56%
Usd Free Cash Flow--20952663.1695815508.998+260%12837935.396+63%20881329.667+0%46399915.224-55%
Usd Free Cash Flow Per Share--0.0190.005+260%0.012+63%0.019+0%0.042-55%
Usd Free Cash Flow To Equity Per Share--0.019-0.012+162%-0.006+132%0.012+55%0.036-48%
Usd Market Cap4614080428.297-9%5028223783.3894959713079.665+1%4131811261.075+22%4322871448.312+16%4612502372.761+9%
Usd Price Per Share4.139-9%4.5104.449+1%3.706+22%3.878+16%4.137+9%
Usd Profit--13933119.36620026786.965-30%21990477.585-37%17447571.087-20%31561181.432-56%
Usd Revenue--125538461.421116188478.908+8%120216442.829+4%118177521.643+6%124684466.982+1%
Usd Total Gains Per Share--0.0140.019-30%0.012+19%0.022-38%0.045-70%
 EOD+4 -4MRQTTM+19 -16YOY+20 -155Y+18 -1710Y+12 -23

3.2. Fundamental Score

Let's check the fundamental score of Shenzhen Salubris Pharmaceuticals Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1582.790
Price to Book Ratio (EOD)Between0-14.148
Net Profit Margin (MRQ)Greater than00.111
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.802
Current Ratio (MRQ)Greater than14.065
Debt to Asset Ratio (MRQ)Less than10.143
Debt to Equity Ratio (MRQ)Less than10.167
Return on Equity (MRQ)Greater than0.150.013
Return on Assets (MRQ)Greater than0.050.011
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Shenzhen Salubris Pharmaceuticals Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.575
Ma 20Greater thanMa 5029.006
Ma 50Greater thanMa 10028.669
Ma 100Greater thanMa 20029.786
OpenGreater thanClose30.300
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Tax Provision  4,32529,01533,340-10,91622,424-5,42117,003-28,839-11,836



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets9,396,673
Total Liabilities1,341,246
Total Stockholder Equity8,018,994
 As reported
Total Liabilities 1,341,246
Total Stockholder Equity+ 8,018,994
Total Assets = 9,396,673

Assets

Total Assets9,396,673
Total Current Assets3,313,222
Long-term Assets6,083,451
Total Current Assets
Cash And Cash Equivalents 1,321,975
Short-term Investments 186,060
Net Receivables 467,399
Inventory 490,857
Other Current Assets 721,816
Total Current Assets  (as reported)3,313,222
Total Current Assets  (calculated)3,188,107
+/- 125,115
Long-term Assets
Property Plant Equipment 1,457,428
Goodwill 10,912
Intangible Assets 2,615,779
Long-term Assets Other 959,681
Long-term Assets  (as reported)6,083,451
Long-term Assets  (calculated)5,043,801
+/- 1,039,650

Liabilities & Shareholders' Equity

Total Current Liabilities815,084
Long-term Liabilities526,162
Total Stockholder Equity8,018,994
Total Current Liabilities
Short Long Term Debt 40,000
Accounts payable 156,007
Other Current Liabilities 35,686
Total Current Liabilities  (as reported)815,084
Total Current Liabilities  (calculated)231,693
+/- 583,391
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt12,539
Long-term Liabilities Other 416,474
Long-term Liabilities  (as reported)526,162
Long-term Liabilities  (calculated)429,012
+/- 97,150
Total Stockholder Equity
Retained Earnings 5,037,427
Total Stockholder Equity (as reported)8,018,994
Total Stockholder Equity (calculated)5,037,427
+/- 2,981,566
Other
Capital Stock1,114,817
Common Stock Shares Outstanding 1,114,817
Net Invested Capital 8,058,994
Net Working Capital 2,498,138
Property Plant and Equipment Gross 1,457,428



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-30
> Total Assets 
1,700,571
1,771,954
1,893,913
1,982,990
2,131,589
2,174,877
2,273,127
2,308,498
2,379,926
2,445,141
2,608,426
2,619,092
2,801,105
2,980,719
3,165,874
3,009,876
3,324,219
3,643,253
3,855,198
3,946,378
3,904,560
4,616,042
4,713,127
4,542,124
5,189,207
5,386,883
5,752,392
5,790,895
6,194,394
6,534,139
6,843,021
6,105,668
6,515,507
6,864,382
7,169,006
6,659,431
7,576,712
7,904,804
8,103,062
7,677,396
7,842,935
7,733,296
8,025,965
7,282,701
7,135,701
6,918,498
6,948,336
9,353,675
9,251,850
9,243,885
9,697,573
9,520,739
9,526,764
9,755,122
9,670,530
9,502,042
9,429,693
9,396,673
9,396,6739,429,6939,502,0429,670,5309,755,1229,526,7649,520,7399,697,5739,243,8859,251,8509,353,6756,948,3366,918,4987,135,7017,282,7018,025,9657,733,2967,842,9357,677,3968,103,0627,904,8047,576,7126,659,4317,169,0066,864,3826,515,5076,105,6686,843,0216,534,1396,194,3945,790,8955,752,3925,386,8835,189,2074,542,1244,713,1274,616,0423,904,5603,946,3783,855,1983,643,2533,324,2193,009,8763,165,8742,980,7192,801,1052,619,0922,608,4262,445,1412,379,9262,308,4982,273,1272,174,8772,131,5891,982,9901,893,9131,771,9541,700,571
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,026,009
3,295,671
3,438,919
3,537,758
3,038,065
3,315,858
3,089,663
3,162,694
2,405,452
2,218,264
2,131,928
2,137,286
4,632,774
4,485,250
4,403,833
4,782,762
4,635,119
4,446,632
4,711,416
4,571,226
3,925,561
3,695,572
3,313,222
3,313,2223,695,5723,925,5614,571,2264,711,4164,446,6324,635,1194,782,7624,403,8334,485,2504,632,7742,137,2862,131,9282,218,2642,405,4523,162,6943,089,6633,315,8583,038,0653,537,7583,438,9193,295,6713,026,00900000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
868,110
457,726
645,111
1,014,578
448,342
1,041,378
1,111,942
1,190,642
1,065,430
901,237
865,135
1,010,804
3,413,299
3,305,265
3,235,871
3,413,441
3,518,410
3,217,370
2,670,467
2,326,772
1,899,792
1,781,161
1,321,975
1,321,9751,781,1611,899,7922,326,7722,670,4673,217,3703,518,4103,413,4413,235,8713,305,2653,413,2991,010,804865,135901,2371,065,4301,190,6421,111,9421,041,378448,3421,014,578645,111457,726868,11000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,000
0
600,000
0
597,770
0
208,000
498,000
300,000
330,000
214,588
51,868
24,043
40,107
60,000
90,675
30,039
70,394
328,362
433,287
206,825
225,762
186,060
186,060225,762206,825433,287328,36270,39430,03990,67560,00040,10724,04351,868214,588330,000300,000498,000208,0000597,7700600,000015,00000000000000000000000000000000000000
       Net Receivables 
169,924
211,687
311,185
367,424
470,353
495,559
597,593
608,029
645,283
686,420
754,040
794,619
874,885
820,682
891,774
955,142
1,027,415
1,140,816
1,211,153
1,175,822
1,212,335
1,307,283
1,409,145
1,596,532
1,633,722
1,439,204
1,590,860
1,530,281
1,423,924
1,476,216
1,359,421
1,401,223
1,427,767
1,438,771
1,451,099
1,545,555
1,358,162
1,539,225
677,462
772,809
867,931
1,180,949
915,159
543,651
525,351
557,205
539,169
541,997
527,364
629,511
755,004
539,838
626,262
581,118
692,764
705,744
603,608
467,399
467,399603,608705,744692,764581,118626,262539,838755,004629,511527,364541,997539,169557,205525,351543,651915,1591,180,949867,931772,809677,4621,539,2251,358,1621,545,5551,451,0991,438,7711,427,7671,401,2231,359,4211,476,2161,423,9241,530,2811,590,8601,439,2041,633,7221,596,5321,409,1451,307,2831,212,3351,175,8221,211,1531,140,8161,027,415955,142891,774820,682874,885794,619754,040686,420645,283608,029597,593495,559470,353367,424311,185211,687169,924
       Other Current Assets 
22,630
69,752
25,490
69,449
99,886
25,014
60,493
52,654
66,519
35,527
30,855
25,939
57,811
155,085
340,597
344,299
367,109
266,410
282,753
82,491
577,713
9,447
19,691
25,452
21,958
43,757
63,405
51,129
65,547
72,267
907,378
98,961
924,934
120,898
911,121
93,443
937,728
83,693
565,053
635,259
388,628
85,618
70,846
79,674
60,776
102,312
123,411
239,368
232,360
57,996
70,801
52,929
68,315
587,935
591,824
82,806
611,848
721,816
721,816611,84882,806591,824587,93568,31552,92970,80157,996232,360239,368123,411102,31260,77679,67470,84685,618388,628635,259565,05383,693937,72893,443911,121120,898924,93498,961907,37872,26765,54751,12963,40543,75721,95825,45219,6919,447577,71382,491282,753266,410367,109344,299340,597155,08557,81125,93930,85535,52766,51952,65460,49325,01499,88669,44925,49069,75222,630
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,565,304
4,639,331
4,527,078
4,643,633
4,863,271
4,877,249
4,917,437
4,786,570
4,811,050
4,720,901
4,766,600
4,840,052
4,914,811
4,885,620
5,080,132
5,043,706
5,099,304
5,576,480
5,734,122
6,083,451
6,083,4515,734,1225,576,4805,099,3045,043,7065,080,1324,885,6204,914,8114,840,0524,766,6004,720,9014,811,0504,786,5704,917,4374,877,2494,863,2714,643,6334,527,0784,639,3314,565,30400000000000000000000000000000000000000
       Property Plant Equipment 
171,435
159,918
212,312
226,079
246,961
402,595
379,803
459,895
428,436
618,350
512,019
667,850
544,696
746,664
638,408
805,356
742,922
938,681
823,552
827,948
834,632
871,993
862,386
854,109
1,011,347
1,036,923
1,050,052
1,048,456
1,070,683
1,081,712
1,073,876
1,112,622
1,140,413
1,180,885
1,237,490
1,231,636
1,254,685
1,266,149
1,277,239
1,298,482
1,309,878
1,410,953
1,425,598
1,424,401
1,466,756
1,507,492
1,541,092
1,605,078
1,644,201
1,637,732
1,567,039
1,536,656
1,545,436
1,505,903
1,489,508
1,485,935
1,491,001
1,457,428
1,457,4281,491,0011,485,9351,489,5081,505,9031,545,4361,536,6561,567,0391,637,7321,644,2011,605,0781,541,0921,507,4921,466,7561,424,4011,425,5981,410,9531,309,8781,298,4821,277,2391,266,1491,254,6851,231,6361,237,4901,180,8851,140,4131,112,6221,073,8761,081,7121,070,6831,048,4561,050,0521,036,9231,011,347854,109862,386871,993834,632827,948823,552938,681742,922805,356638,408746,664544,696667,850512,019618,350428,436459,895379,803402,595246,961226,079212,312159,918171,435
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,545
87,138
87,138
87,138
87,138
87,138
87,138
87,138
87,138
87,138
87,138
87,138
617,954
380,846
380,846
380,846
380,846
369,858
369,858
369,858
369,858
87,138
87,138
87,138
87,138
87,138
87,138
87,138
87,138
60,527
60,527
60,527
60,527
10,912
10,91260,52760,52760,52760,52787,13887,13887,13887,13887,13887,13887,13887,138369,858369,858369,858369,858380,846380,846380,846380,846617,95487,13887,13887,13887,13887,13887,13887,13887,13887,13887,13887,13821,545000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
586,665
622,345
718,040
800,501
803,751
800,798
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000800,798803,751800,501718,040622,345586,66500000000000000000000000000000000000
       Intangible Assets 
50
821
15,888
677
66,842
598
50,135
581
89,953
12,740
155,884
11,704
160,729
10,360
169,450
9,248
173,659
346,754
476,786
475,811
474,347
984,712
983,255
981,729
1,098,475
1,086,086
1,084,365
1,082,652
1,081,979
1,064,630
1,065,116
1,061,303
1,059,954
1,060,058
1,058,401
931,037
918,680
1,062,499
1,850,065
1,747,685
1,714,503
1,734,750
1,744,490
1,731,646
1,902,195
1,981,685
2,005,116
2,095,615
2,123,177
2,011,017
2,094,901
2,091,702
2,181,133
2,184,536
2,232,892
2,427,204
2,505,347
2,615,779
2,615,7792,505,3472,427,2042,232,8922,184,5362,181,1332,091,7022,094,9012,011,0172,123,1772,095,6152,005,1161,981,6851,902,1951,731,6461,744,4901,734,7501,714,5031,747,6851,850,0651,062,499918,680931,0371,058,4011,060,0581,059,9541,061,3031,065,1161,064,6301,081,9791,082,6521,084,3651,086,0861,098,475981,729983,255984,712474,347475,811476,786346,754173,6599,248169,45010,360160,72911,704155,88412,74089,95358150,13559866,84267715,88882150
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
516,266
328,674
204,239
123,974
295,369
289,833
1,609,863
169,612
174,540
92,473
68,531
207,137
205,672
217,591
310,770
320,832
325,201
613,207
661,835
959,681
959,681661,835613,207325,201320,832310,770217,591205,672207,13768,53192,473174,540169,6121,609,863289,833295,369123,974204,239328,674516,26600000000000000000000000000000000000000
> Total Liabilities 
157,825
148,586
182,954
295,734
367,415
309,500
302,002
383,458
364,350
310,517
347,753
395,779
394,711
374,024
357,008
314,768
428,489
508,363
464,434
705,071
409,921
827,954
609,736
590,562
866,862
691,251
699,874
1,030,515
1,072,104
1,074,072
1,011,012
657,946
709,612
705,863
602,252
551,226
1,059,751
1,033,600
911,898
1,012,371
1,114,795
1,066,924
1,342,975
1,468,153
1,268,274
1,326,837
1,200,649
1,207,777
1,285,571
1,198,241
1,642,996
1,841,430
1,690,773
1,778,576
1,484,275
1,701,637
1,484,420
1,341,246
1,341,2461,484,4201,701,6371,484,2751,778,5761,690,7731,841,4301,642,9961,198,2411,285,5711,207,7771,200,6491,326,8371,268,2741,468,1531,342,9751,066,9241,114,7951,012,371911,8981,033,6001,059,751551,226602,252705,863709,612657,9461,011,0121,074,0721,072,1041,030,515699,874691,251866,862590,562609,736827,954409,921705,071464,434508,363428,489314,768357,008374,024394,711395,779347,753310,517364,350383,458302,002309,500367,415295,734182,954148,586157,825
   > Total Current Liabilities 
154,825
145,586
179,954
292,734
352,945
292,857
285,616
357,328
338,476
283,906
311,548
357,521
357,345
332,851
315,727
275,279
393,806
475,806
433,094
669,237
374,422
793,038
576,070
557,846
771,609
598,993
605,039
928,886
971,438
968,549
906,511
542,219
594,455
573,109
478,561
432,663
813,021
675,089
557,712
686,023
754,353
777,500
928,921
1,022,231
1,044,618
1,096,990
967,618
969,132
1,130,399
1,012,841
1,431,006
1,632,797
1,470,273
1,603,636
1,319,342
1,146,433
934,708
815,084
815,084934,7081,146,4331,319,3421,603,6361,470,2731,632,7971,431,0061,012,8411,130,399969,132967,6181,096,9901,044,6181,022,231928,921777,500754,353686,023557,712675,089813,021432,663478,561573,109594,455542,219906,511968,549971,438928,886605,039598,993771,609557,846576,070793,038374,422669,237433,094475,806393,806275,279315,727332,851357,345357,521311,548283,906338,476357,328285,616292,857352,945292,734179,954145,586154,825
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,000
15,000
15,000
15,000
94,000
124,000
124,000
175,818
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000175,818124,000124,00094,00015,00015,00015,00015,00000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,000
15,000
15,000
15,000
94,000
124,000
124,000
175,818
235,818
235,818
300,260
322,773
230,188
115,518
62,999
180,353
228,538
160,087
177,186
60,549
195,379
189,614
40,000
40,000189,614195,37960,549177,186160,087228,538180,35362,999115,518230,188322,773300,260235,818235,818175,818124,000124,00094,00015,00015,00015,00015,00000000000000000000000000000000000000
       Accounts payable 
85,063
82,484
83,188
125,643
200,623
207,995
187,894
187,460
167,455
149,238
146,936
173,192
162,912
121,522
100,133
78,941
104,069
167,085
122,571
116,892
102,798
104,969
125,533
137,856
320,305
169,814
188,079
99,119
101,424
41,079
82,261
152,767
154,913
67,310
119,222
104,017
125,039
103,284
129,522
115,357
166,257
144,059
175,130
134,716
104,500
223,387
173,325
132,182
204,885
187,672
201,158
188,321
210,907
219,647
203,256
137,444
128,941
156,007
156,007128,941137,444203,256219,647210,907188,321201,158187,672204,885132,182173,325223,387104,500134,716175,130144,059166,257115,357129,522103,284125,039104,017119,22267,310154,913152,76782,26141,079101,42499,119188,079169,814320,305137,856125,533104,969102,798116,892122,571167,085104,06978,941100,133121,522162,912173,192146,936149,238167,455187,460187,894207,995200,623125,64383,18882,48485,063
       Other Current Liabilities 
69,762
63,102
96,766
167,091
152,322
84,862
97,722
169,868
171,021
134,668
164,612
184,329
194,433
211,329
215,594
196,338
289,737
308,721
310,523
552,344
271,623
688,069
450,536
419,990
451,304
429,179
416,961
829,767
870,014
912,471
809,250
374,452
424,542
490,799
344,339
129,011
550,405
283,253
15,000
37,704
15,000
95,244
464,702
275,382
408,086
236,221
380,981
306,155
658,967
273,517
899,245
691,504
900,607
986,720
901,812
304,864
420,126
35,686
35,686420,126304,864901,812986,720900,607691,504899,245273,517658,967306,155380,981236,221408,086275,382464,70295,24415,00037,70415,000283,253550,405129,011344,339490,799424,542374,452809,250912,471870,014829,767416,961429,179451,304419,990450,536688,069271,623552,344310,523308,721289,737196,338215,594211,329194,433184,329164,612134,668171,021169,86897,72284,862152,322167,09196,76663,10269,762
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
354,186
326,348
360,441
289,423
414,055
445,922
223,656
229,847
233,031
238,645
155,173
185,400
211,990
208,633
220,500
174,940
164,934
555,204
549,712
526,162
526,162549,712555,204164,934174,940220,500208,633211,990185,400155,173238,645233,031229,847223,656445,922414,055289,423360,441326,348354,18600000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-15,000
-15,000
-15,000
-15,000
-94,000
-124,000
-124,000
-175,818
0
0
0
15,698
12,368
14,413
9,113
7,579
6,608
29,001
19,583
19,545
16,463
21,394
12,539
12,53921,39416,46319,54519,58329,0016,6087,5799,11314,41312,36815,698000-175,818-124,000-124,000-94,000-15,000-15,000-15,000-15,00000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
267,234
239,527
25,191
24,710
24,640
24,161
23,884
30,412
25,696
24,444
24,444
82,573
98,896
90,979
85,304
29,641
28,997
407,697
411,179
416,474
416,474411,179407,69728,99729,64185,30490,97998,89682,57324,44424,44425,69630,41223,88424,16124,64024,71025,191239,527267,23400000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
511,279
574,774
836,021
873,433
922,762
758,507
670,222
693,633
715,263
685,182
816,835
860,922
949,236
1,002,405
1,047,147
1,235,501
1,233,925
1,323,891
1,343,830
1,427,709
1,154,080
1,262,844
0
01,262,8441,154,0801,427,7091,343,8301,323,8911,233,9251,235,5011,047,1471,002,405949,236860,922816,835685,182715,263693,633670,222758,507922,762873,433836,021574,774511,27900000000000000000000000000000000000
> Total Stockholder Equity
1,540,779
1,621,435
1,709,124
1,685,301
1,762,161
1,863,250
1,968,922
1,922,790
2,013,235
2,132,298
2,258,317
2,220,914
2,403,858
2,603,984
2,805,950
2,691,724
2,891,545
3,129,334
3,383,484
3,232,323
3,488,433
3,779,536
4,094,157
3,941,676
4,249,953
4,589,515
4,946,626
4,656,093
5,001,327
5,360,326
5,736,014
5,354,984
5,716,542
6,052,938
6,465,037
6,004,184
6,370,431
6,660,928
6,982,460
6,457,095
6,544,291
6,489,456
6,506,944
5,734,109
5,788,629
5,508,330
5,666,495
8,066,509
7,953,723
8,033,734
8,042,745
7,670,535
7,821,605
7,940,734
8,151,064
7,765,014
7,909,904
8,018,994
8,018,9947,909,9047,765,0148,151,0647,940,7347,821,6057,670,5358,042,7458,033,7347,953,7238,066,5095,666,4955,508,3305,788,6295,734,1096,506,9446,489,4566,544,2916,457,0956,982,4606,660,9286,370,4316,004,1846,465,0376,052,9385,716,5425,354,9845,736,0145,360,3265,001,3274,656,0934,946,6264,589,5154,249,9533,941,6764,094,1573,779,5363,488,4333,232,3233,383,4843,129,3342,891,5452,691,7242,805,9502,603,9842,403,8582,220,9142,258,3172,132,2982,013,2351,922,7901,968,9221,863,2501,762,1611,685,3011,709,1241,621,4351,540,779
   Common Stock
113,500
113,500
113,500
227,000
227,000
227,000
227,000
363,200
363,200
363,200
363,200
435,840
435,840
435,840
435,840
653,760
653,760
653,760
653,760
653,760
653,760
653,760
653,760
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,046,016
1,114,817
1,114,817
1,114,817
1,114,817
1,114,817
1,114,817
1,114,817
1,114,817
1,114,817
1,114,817
0
01,114,8171,114,8171,114,8171,114,8171,114,8171,114,8171,114,8171,114,8171,114,8171,114,8171,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,0161,046,016653,760653,760653,760653,760653,760653,760653,760653,760435,840435,840435,840435,840363,200363,200363,200363,200227,000227,000227,000227,000113,500113,500113,500
   Retained Earnings 
295,933
352,627
440,315
416,492
493,352
559,246
664,918
618,786
709,248
788,353
914,370
876,993
1,059,937
1,197,669
1,399,592
1,285,418
1,485,227
1,643,940
2,155,562
2,004,401
2,260,542
2,551,442
2,865,017
2,712,888
3,019,496
3,359,503
3,717,338
3,426,240
3,771,472
4,128,308
4,504,731
4,126,509
4,490,142
4,847,984
5,263,306
4,800,861
5,161,178
5,469,394
5,267,976
4,742,137
4,826,517
5,345,064
5,495,154
4,992,851
5,063,715
4,797,751
4,952,057
5,030,166
5,148,657
5,329,877
5,567,255
5,240,596
5,431,920
5,002,893
5,740,353
5,321,349
5,462,900
5,037,427
5,037,4275,462,9005,321,3495,740,3535,002,8935,431,9205,240,5965,567,2555,329,8775,148,6575,030,1664,952,0574,797,7515,063,7154,992,8515,495,1545,345,0644,826,5174,742,1375,267,9765,469,3945,161,1784,800,8615,263,3064,847,9844,490,1424,126,5094,504,7314,128,3083,771,4723,426,2403,717,3383,359,5033,019,4962,712,8882,865,0172,551,4422,260,5422,004,4012,155,5621,643,9401,485,2271,285,4181,399,5921,197,6691,059,937876,993914,370788,353709,248618,786664,918559,246493,352416,492440,315352,627295,933
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-3,785
2,144
1,159
1,102
1,575
4,392
17,151
24,742
22,987
6,644
-7,692
-3,833
-2,135
1,154
-13,413
-17,055
10,680
40,224
33,245
25,445
51,850
48,642
0
048,64251,85025,44533,24540,22410,680-17,055-13,4131,154-2,135-3,833-7,6926,64422,98724,74217,1514,3921,5751,1021,1592,144-3,78500000000000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue3,365,343
Cost of Revenue-1,057,552
Gross Profit2,307,7922,307,792
 
Operating Income (+$)
Gross Profit2,307,792
Operating Expense-2,722,087
Operating Income643,256-414,295
 
Operating Expense (+$)
Research Development409,194
Selling General Administrative1,118,398
Selling And Marketing Expenses0
Operating Expense2,722,0871,527,592
 
Net Interest Income (+$)
Interest Income68,644
Interest Expense-17,373
Other Finance Cost-498
Net Interest Income50,774
 
Pretax Income (+$)
Operating Income643,256
Net Interest Income50,774
Other Non-Operating Income Expenses0
Income Before Tax (EBT)641,761643,256
EBIT - interestExpense = -17,373
580,066
597,439
Interest Expense17,373
Earnings Before Interest and Taxes (EBIT)0659,133
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax641,761
Tax Provision-60,932
Net Income From Continuing Ops580,829580,829
Net Income580,066
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-50,774
 

Technical Analysis of Salubris
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Salubris. The general trend of Salubris is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Salubris's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Shenzhen Salubris Pharmaceuticals Co Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 32.44 < 33.16 < 33.82.

The bearish price targets are: 29.90 > 29.85 > 29.85.

Tweet this
Shenzhen Salubris Pharmaceuticals Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Shenzhen Salubris Pharmaceuticals Co Ltd. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shenzhen Salubris Pharmaceuticals Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Shenzhen Salubris Pharmaceuticals Co Ltd. The current macd is 0.25631271.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Salubris price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Salubris. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Salubris price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Shenzhen Salubris Pharmaceuticals Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartShenzhen Salubris Pharmaceuticals Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Shenzhen Salubris Pharmaceuticals Co Ltd. The current adx is 17.18.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Salubris shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Shenzhen Salubris Pharmaceuticals Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Shenzhen Salubris Pharmaceuticals Co Ltd. The current sar is 27.97.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Shenzhen Salubris Pharmaceuticals Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Shenzhen Salubris Pharmaceuticals Co Ltd. The current rsi is 57.58. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Shenzhen Salubris Pharmaceuticals Co Ltd Daily Relative Strength Index (RSI) ChartShenzhen Salubris Pharmaceuticals Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Shenzhen Salubris Pharmaceuticals Co Ltd. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Salubris price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Shenzhen Salubris Pharmaceuticals Co Ltd Daily Stochastic Oscillator ChartShenzhen Salubris Pharmaceuticals Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Shenzhen Salubris Pharmaceuticals Co Ltd. The current cci is 155.31.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Shenzhen Salubris Pharmaceuticals Co Ltd Daily Commodity Channel Index (CCI) ChartShenzhen Salubris Pharmaceuticals Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Shenzhen Salubris Pharmaceuticals Co Ltd. The current cmo is 19.69.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Shenzhen Salubris Pharmaceuticals Co Ltd Daily Chande Momentum Oscillator (CMO) ChartShenzhen Salubris Pharmaceuticals Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Shenzhen Salubris Pharmaceuticals Co Ltd. The current willr is -24.35424354.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Salubris is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Shenzhen Salubris Pharmaceuticals Co Ltd Daily Williams %R ChartShenzhen Salubris Pharmaceuticals Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Shenzhen Salubris Pharmaceuticals Co Ltd.

Shenzhen Salubris Pharmaceuticals Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Shenzhen Salubris Pharmaceuticals Co Ltd. The current atr is 0.95844232.

Shenzhen Salubris Pharmaceuticals Co Ltd Daily Average True Range (ATR) ChartShenzhen Salubris Pharmaceuticals Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Shenzhen Salubris Pharmaceuticals Co Ltd. The current obv is 104,089,785.

Shenzhen Salubris Pharmaceuticals Co Ltd Daily On-Balance Volume (OBV) ChartShenzhen Salubris Pharmaceuticals Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Shenzhen Salubris Pharmaceuticals Co Ltd. The current mfi is 47.46.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Shenzhen Salubris Pharmaceuticals Co Ltd Daily Money Flow Index (MFI) ChartShenzhen Salubris Pharmaceuticals Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Shenzhen Salubris Pharmaceuticals Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-25ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Shenzhen Salubris Pharmaceuticals Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Shenzhen Salubris Pharmaceuticals Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.575
Ma 20Greater thanMa 5029.006
Ma 50Greater thanMa 10028.669
Ma 100Greater thanMa 20029.786
OpenGreater thanClose30.300
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Salubris with someone you think should read this too:
  • Are you bullish or bearish on Salubris? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Salubris? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Shenzhen Salubris Pharmaceuticals Co Ltd

I send you an email if I find something interesting about Shenzhen Salubris Pharmaceuticals Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Shenzhen Salubris Pharmaceuticals Co Ltd.

Receive notifications about Shenzhen Salubris Pharmaceuticals Co Ltd in your mailbox!